

## Technical Data Sheet

## Immuno-Oncology Protein Panel

## Product Information

<b>Material Number:</b>	572316
<b>Size:</b>	2 Tests
<b>Reactivity:</b>	Tested in Development: Human
<b>Storage Buffer:</b>	Lyophilized powder containing BSA and $\leq 0.25\%$ sodium azide
<b>Component:</b>	51-9024945
<b>Description:</b>	T-Cell Protein Panel
<b>Size:</b>	1 Test (2 each)
<b>Component:</b>	51-9024946
<b>Description:</b>	B-Cell Protein Panel
<b>Size:</b>	1 Test (2 each)
<b>Component:</b>	51-9025129
<b>Description:</b>	Tumor Protein Panel
<b>Size:</b>	1 Test (2 each)

## Description

The BD® OMICS-One Immuno-Oncology Protein Panel consists of six single tubes: two tubes of T-Cell Protein Panel (1 test/tube) containing 30 different specificities against major T-cell markers, two tubes of B-Cell Protein Panel (1 test/tube) containing 30 different specificities against major B-cell markers, and two tubes of Tumor Protein Panel (1 test/tube) containing 30 different specificities against major Tumor markers. Designed and optimized to work on the BD Rhapsody™ System, the Immuno-Oncology Protein Panel is tested to work seamlessly alongside the BD Rhapsody™ Whole Transcriptome Analysis (WTA) Assay, Targeted mRNA Assay, BD® Single-Cell Multiplexing Kit (SMK), BD® Intracellular CITE-seq (IC-AbSeq) Assay, and BD Rhapsody™ TCR/BCR Next Multiomic Assay for human. The individual antibodies were each conjugated to an oligonucleotide that contains a specific antibody barcode sequence flanked by a polyA tail on the 3' end and a common PCR handle (PCR primer binding site) on the 5' end. All AbSeq barcode sequences were generated *in silico* with minimal sequence similarity to the human genomes, have low predicted secondary structure, and have high Hamming distance within the BD antibody-oligo portfolio, to allow for sequencing error correction and unique mapping. The polyA tail of the oligonucleotide allows the barcode sequence to be captured by the BD Rhapsody™ Enhanced Cell Capture Beads. The 5' PCR handle allows for efficient library generation for various sequencing platforms. Each individual antibody exists at an optimal concentration within the 59-plex panel to enable superior target and population resolution.

The Immuno-Oncology Protein Panel is designed with SMART technology. SMART technology helps lower sequencing cost while increasing data resolution by attenuating antibodies that target high-expressing primary markers and allowing reallocation of sequencing reads to markers expressed at lower levels. With SMART technology, markers low in expression can be quantified without having to do deeper sequencing and incurring high sequencing cost. There are six specificities attenuated in the Immuno-Oncology Protein Panel: CD4, CD43, CD44, CD45, HLA-DR, and HLA-ABC.

## Preparation and Storage

Store at 2–8°C and protected from prolonged exposure to light. Do not freeze.

## Application Notes

<b>Application:</b>	Single Cell 3' Sequencing (Qualified)
<b>Barcode Sequence:</b>	Specific for each individual AbSeq antibody (see panel tables on pages 3 and 5)
<b>Sequence ID:</b>	Specific for each individual AbSeq antibody (see panel tables on pages 3 and 5)

## BD Biosciences

bdbiosciences.com

United States 877.232.8995	Canada 866.979.9408	Europe 32.2.400.98.95	Japan 0120.8555.90	Asia Pacific 65.6861.0633	Latin America/Caribbean 55.11.5185.9995
-------------------------------	------------------------	--------------------------	-----------------------	------------------------------	--

For country contact information, visit [bdbiosciences.com/contact](https://bdbiosciences.com/contact).

*Conditions: The information disclosed herein is not to be construed as a recommendation to use the above product in violation of any patents. BD Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Purchase does not include or carry any right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.*

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale.

© 2025 BD. BD, the BD Logo and all other trademarks are the property of Becton, Dickinson and Company.

572316 Rev. 01



## Recommended Assay Procedure

**Note:** The protocol supports the Ab-Oligos labeling of 1–2 million cells per tube.

1. Remove one tube of BD<sup>®</sup> OMICS-One T-Cell Protein Panel, one tube of BD<sup>®</sup> OMICS-One B-Cell Protein Panel, and one tube of BD<sup>®</sup> OMICS-One Tumor Protein Panel from foil bags and bring up to room temperature for 5 minutes.
2. Make sure all pellets are located at the bottom of the tubes. If not, briefly centrifuge to collect the contents at the tube bottom.
3. For each tube, add 35  $\mu$ L of nuclease-free water to the bottom of the tube and allow antibodies to reconstitute for 5 minutes at room temperature.
4. Transfer the reconstituted antibodies on ice until the cells are ready for staining.

**Note:** Reconstitute antibody immediately before cell staining. Prolonged incubation of reconstituted antibody may increase the non-specific background.

5. For BD<sup>®</sup> AbSeq Ab-Oligo drop-in of 25 plex or lower, prepare the BD<sup>®</sup> AbSeq labeling MasterMix in 1.5-mL LoBind tube on ice. The following calculation is for procedure with Optional Fc Block. If Fc Block is not performed, add 25  $\mu$ L BD Pharmingen<sup>™</sup> Stain Buffer (FBS) to the Abseq labeling MasterMix total volume for each sample.

**Note:** For drop-in with more than 25 plex, reach out to technical support for calculation.

For sequential labeling with Sample Tags or no Sample Tags, prepare BD<sup>®</sup> AbSeq labeling MasterMix for drop-ins as specified in the following table.

Component	1 sample ( $\mu$ L)	1 sample + 30% overage ( $\mu$ L)	2 samples + 30% overage ( $\mu$ L)
Per BD <sup>®</sup> AbSeq Ab-Oligo	2.0	2.6	5.2
Total of AbSeq Ab-Oligo (N = Number of drop-in antibodies) N=0 if no drop-in antibodies	$2.0 \times N$	$2.6 \times N$	$5.2 \times N$
BD Pharmingen <sup>™</sup> Stain Buffer (FBS) (catalog number 554656)	$70 - (2.0 \times N)$	$91 - (2.6 \times N)$	$182 - (5.2 \times N)$
<b>Total</b>	<b>70</b>	<b>91</b>	<b>182</b>

For co-labeling with Sample Tags, prepare BD<sup>®</sup> AbSeq labeling MasterMix for drop-ins as specified in the following table.

Component	1 sample ( $\mu$ L)	1 sample + 30% overage ( $\mu$ L)	2 samples + 30% overage ( $\mu$ L)
Per BD <sup>®</sup> AbSeq Ab-Oligo	2.0	2.6	5.2
Total of AbSeq Ab-Oligo (N = Number of drop-in antibodies) N=0 if no drop-in antibodies	$2.0 \times N$	$2.6 \times N$	$5.2 \times N$
BD Pharmingen <sup>™</sup> Stain Buffer (FBS) (catalog number 554656)	$50 - (2.0 \times N)$	$65 - (2.6 \times N)$	$130 - (5.2 \times N)$
<b>Total</b>	<b>50</b>	<b>65</b>	<b>130</b>

6. Pipet-mix the BD<sup>®</sup> AbSeq labeling MasterMix for drop-ins. Briefly centrifuge to collect the contents at the bottom, and place back on ice.
7. For sequential labeling with Sample Tags or no Sample Tags, for each sample, combine the three tubes containing 35  $\mu$ L reconstituted T-Cell Protein Panel solution, 35  $\mu$ L reconstituted B-Cell Protein Panel solution, and 35  $\mu$ L reconstituted Tumor Protein Panel solution. Then add 70  $\mu$ L BD<sup>®</sup> AbSeq labeling MasterMix of drop-ins to the tube containing 105  $\mu$ L reconstituted T-Cell, B-Cell, and Tumor Protein Panel solution to make a total volume of 175  $\mu$ L.

For co-labeling with Sample Tags, for each sample, combine the three tubes containing 35  $\mu$ L reconstituted T-Cell Protein Panel solution, 35  $\mu$ L reconstituted B-Cell Protein Panel solution, and 35  $\mu$ L reconstituted Tumor Protein Panel solution. Then add 50  $\mu$ L BD<sup>®</sup> AbSeq labeling MasterMix of drop-ins and 20  $\mu$ L Sample Tag to the tube containing total 105  $\mu$ L reconstituted T-Cell, B-Cell, and Tumor Protein Panel solution to make a total volume of 175  $\mu$ L.

8. Pipet-mix the mixture, briefly centrifuge to collect the contents at the tube bottom, and place back on ice.
9. Centrifuge cells at  $400 \times g$  for 5 minutes. If Fc Block is used, proceed to step 10. If Fc Block is not used, skip to step 11.
10. (Optional) For samples containing myeloid and B lymphocytes, BD Biosciences recommends blocking nonspecific Fc Receptor-mediated false-positive signals with Human BD Fc Block (catalog number 564220).

- a. To perform blocking, pipet the Fc Block MasterMix into a new 1.5-mL LoBind tube on ice:

Component	1 sample ( $\mu$ L)*	1 sample + 20% overage ( $\mu$ L)
BD Pharmingen <sup>™</sup> Stain Buffer (FBS) (catalog number 554656)	20.0	24.0
BD Pharmingen <sup>™</sup> Human BD Fc Block (catalog number 564220)	5.0	6.0
<b>Total</b>	<b>25.0</b>	<b>30.0</b>

\* Sufficient for up to 1,000,000 cells. To block more cells, adjust the volume.

- b. Pipet-mix the Fc Block MasterMix and briefly centrifuge. Place on ice.
  - c. Remove the supernatant from the cells without disturbing the pellet.
  - d. Resuspend the cells in 25  $\mu$ L of Fc Block MasterMix.
  - e. Incubate the cells at room temperature (15°C to 25°C) for 10 minutes.
  - f. Add 175  $\mu$ L of BD<sup>®</sup> AbSeq labeling MasterMix from Step 8 into the cell suspension. Pipet-mix and proceed to Step 12.
11. Remove the supernatant from the cells without disturbing the pellet. Add 25  $\mu$ L Stain Buffer (FBS) to the 175  $\mu$ L of BD<sup>®</sup> AbSeq labeling MasterMix from Step 8 to make a total volume of 200  $\mu$ L. Resuspend the cell pellet in 200  $\mu$ L total volume. Pipet-mix.

12. Transfer the cells with BD® AbSeq labeling MasterMix into a new 5-mL polystyrene Falcon tube.
13. Stain the cells on ice for 30 minutes.
14. Add 3-4 mL Stain Buffer (FBS) to labelled cells and pipet-mix.
15. Centrifuge at 400 x g for 5 minutes.
16. Uncap the tube and invert to decant supernatant into biohazardous waste. Keep the tube inverted and gently blot on a lint-free wiper to remove residual supernatant from tube rim.
17. Repeat steps 14-16 twice more for a total of 3 washes.
18. Resuspend the final washed cell pellet in 620 µL cold Sample Buffer from the BD Rhapsody™ Enhanced Cartridge Reagent V3 (catalog number 667052) and proceed to single cell capture with on-cartridge washing described in substeps a–c. Refer to the *BD Rhapsody™ HT Single-Cell Analysis System Single-Cell Capture and cDNA Synthesis Protocol* (Doc ID 23-24252) or *BD Rhapsody™ HT Xpress System Single-Cell Capture and cDNA Synthesis Protocol* (Doc ID 23-24253) for additional details.

**Note:** Perform on-cartridge washing after cell settling (8-minute incubation) as described in the following sub-steps.

- a. At the protocol section of “Loading cells in BD Rhapsody™ 8-Lane Cartridge”, after cell load, incubate the cartridge in dark at room temperature for 8 minutes.
- b. Place the cartridge on the BD Rhapsody™ HT Xpress and perform the On-Cartridge Wash steps listed as follows:

Material to load	Volume (µL) 1 lane	Pipette Mode
Air	380	Prime/Wash
Cold Sample Buffer	380	Prime/Wash
Air	380	Prime/Wash
Cold Sample Buffer	380	Prime/Wash

- c. (Optional) Perform the scanner step: Cell Load Scan, if using *BD Rhapsody™ HT Single-Cell Analysis System Single-Cell Capture and cDNA Synthesis Protocol* (Doc ID 23-24252). No need for 8-minute delay before scanning.

**Warning:** All biological specimens and materials are considered biohazardous. Handle as if capable of transmitting infection and dispose using proper precautions in accordance with federal, state, and local regulations. Never pipette by mouth. Wear suitable protective clothing, eyewear, and gloves.

**List of all 30 Human AbSeq specificities included in the BD® OMICS-One T-Cell Panel:**

Specificity	Clone	Oligo ID	BD® AbSeq Barcode Sequence
CD103	Ber-ACT8	AHS0001	AAATAGTATCGAGCGTAGTTAAGTTGCGTAGCCGTT
CD137	4B4-1	AHS0003	TGACAAGCAACGAGCGATACGAAAGGCGAAATTAGT
CD45RA	HI100	AHS0009	AAGCGATTGCGAAGGGTTAGTCAGTACGTTATGTTG
CD69	FN50	AHS0010	CAATAACGGGTCATAGTAAGTCGCGAGTAAGAGGGC
CD278	DX29	AHS0012	ATAGTCCGCCGTAATCGTTGTGTCGCTGAAAGGGTT
CD134 (OX40)	ACT35	AHS0013	GGTGTGGTAAGACGGACGGAGTAGATATTCGAGGT
CD279 (PD-1) <sup>†</sup>	EH12.1	AHS0014	ATGGTAGTATCACGACGTAGTAGGGTAATTGGCAGT
CD366 (TIM-3)	7D3	AHS0016	TAGGTAGTAGTCCCGTATATCCGATCCGTGTTGTTT
CD223 (Lag3)	T47-530	AHS0018	CGGCATGAATTAGGCGAGACTTAGTATACGAGCTGG
CD95 (Fas)*	DX2	AHS0023	GGCCCGTTAGAGTTGGTATCCGTATGAAGGTTAGCT
CD25	2A3	AHS0026	AGTTGTATGGGTTAGCCGAGAGTAGTGCCTATGATT
CD127	HIL-7R-M21	AHS0028	AGTTATTAGGCTCGTAGGTATGTTTAGGTTATCGCG
CD183	1C6/CXCR3	AHS0031	AAAGTGTTGGCGTTATGTGTTTCGTTAGCGGTGTGGG
CD4	SK3	AHS0032	TCGGTGTTATGAGTAGGTCGTCGTGCGGTTTGATGT
CD196 (CCR6)	11A9	AHS0034	ACGTGTTATGGTGTTGTTTCAATTGTGGTAGTCAGT
CD45RO	UCHL1	AHS0036	TGAGAGGTTATTGGGCGTATGACTTCGGTGATTGTG
CD194 (CCR4)	1G1	AHS0038	AATATTAGTGGGTCTCGCGTTGGCCGGTTGTTAGT
CD62L	DREG-56	AHS0049	ATGGTAAATATGGGCGAATGCGGTTGTGCTAAAGT
CD272	J168-540	AHS0052	GTAGGTTGATAGTCGGCGATAGTGCGGTTGAAAGCT
CD154	TRAP1	AHS0077	TAAGAGGTAAGTGCATTCGGGTATAGGCGTGATTTG
CD357 (GITR)	V27-580	AHS0104	TCTGTGTGTCGGGTTGAATCGTAGTGAGTTAGCGTG
CD28	L293	AHS0138	TTGTTGAGGATACGATGAAGCGGTTTAAGGGTGTGG
TCRgd	11F2	AHS0142	CTCGTGGGTTAGGCTTGATCGTAGTTATGTATGGTT
CD44 <sup>†</sup>	L178	AHS0167	GTGATTGATTAGGACAGTTTCGTTGCTTAGTAGTGGG
TCR V $\alpha$ 24-J $\alpha$ 18	6B11	AHS0175	TTCTGGTTCGGTTGAGCTACTAATTTTCGTTGGATGG
CD161 (KLRB1)	HP-3G10	AHS0205	TTTAGGACGATTAGTTGTGCGGCATAGGAGGTGTTC
CD8	SK1	AHS0228	AGGACATAGAGTAGGACGAGGTAGGCTTAAATTGCT
CD3	UCHT1	AHS0231	AGCTAGGTGTTATCGGCAAGTTGTACGGTGAAGTCG
CD197 (CCR7)	2-L1-A	AHS0273	AATGTGTGATCGGCAAAGGGTTCTCGGGTTAATATG
TIGIT	tgMab-2	AHS0411	AGAGGGTTTAGTCAAGGTCGTGCGTATAGTTTCAGGT

**List of all 30 Human AbSeq specificities included in the BD® OMICS-One B-Cell Panel:**

Specificity	Clone	Oligo ID	BD® AbSeq Barcode Sequence
CD20	2H7	AHS0008	TTGCTTGTTCGCGTTAGAGAGTATGTCGGGAGATG
CD275	2D3/B7-H2	AHS0011	GTTTATATGTACGACGCCCGTTGACGAGTGGAAAGT
CD38	HIT2	AHS0022	GTCAACGATGGGTAGCGGTAGAAATAACGGAAGTGG
CD95*	DX2	AHS0023	GGCCCGTTAGAGTTGGTATCCGTATGAAGGTTAGCT
CD27	M-T271	AHS0025	TGTCCGGTTTAGCGAATTGGGTTGAGTCACGTAGGT
CD19	SJ25C1	AHS0030	TAGTAATGTGTTCTGTAGCCGGTAATAATCTTCGTGG
HLA-DR	G46-6	AHS0035	TGTTGGTTATTCGTTAGTGCATCCGTTTGGGCGTGG
CD185 (CXCR5)	RF8B2	AHS0039	AGGAAGGTCGATTGTATAACGCGGCATTGTAACGGC
CD24 <sup>+</sup>	ML5	AHS0042	ACTTTGGGTTGAGCGCATGATTATTCGTGACACTTT
CD80	L307.4	AHS0046	GAGGGTAACGGGTGTCCAAATATCGGCTGTGTAAGT
CD5	UCHT2	AHS0047	ACGAAGCGAGCGAAGAACCATGCGATTGAGTAAGT
CD10	HI10a	AHS0051	CCTGTTTGATGCGTACGGAGATTTAGCGGATTTATG
IgD	IA6-2	AHS0058	TGAGGGATGTATAGCGAGAATTGCGACCGTAGACTT
IgG	G18-145	AHS0059	AGGTAGGTTATCGTAGGGTAGACTTAGCGGGCATTG
CD184 (CXCR4)	12G5	AHS0060	CAGTGTTTAGAGCGGGTTGCATATGTCGTTTAGAGG
CD34 <sup>+</sup>	581	AHS0061	TGGGTGTATTACGGTTAGTTTATGCGCGAAGGTGTT
CD21	B-ly4	AHS0074	GTATTCGCGTATTGTGTCAGTCGGTAGGGTTATGGTCT
CD9	M-L13	AHS0082	GGGTTGTAAGTCGTCGGAAGTGTGAAGCGTATAGTG
CD126	M5	AHS0096	AATGGTGAATCGCCCTAGCAAGTGGTATCGGAATCG
CD30	BERH8	AHS0114	CCAGTGTAGATTGAGCCGTCGATTTAGTTAGCAGTG
CD40	5C3	AHS0117	GGTGTAATTGGGCTAGAACGTATATGCGGTAAGGCG
CD138	MI15	AHS0121	TAAGCTGCCGGTATTGGAAACGTATCGATCTATTGG
CD79B	CB3-1	AHS0153	CATCATGAGTAGTTGCTTCGGCGAGTAGGTTTAATT
CD22	HIB22	AHS0195	TGGTTCGTGACTGTATAGGCTTAGCTTAGGCAATTT
IgM	G20-127	AHS0198	TTTGGAGGGTAGCTAGTTGCAGTTCGTGGTCGTTTC
CD43	1G10	AHS0200	ATGGCGGATGGATTTGTCGGTGATATTGCTCTCGTT
CD268 (BAFF-R)	11C1	AHS0206	TGTGAATGAGTTAAGCGTCGCGGATATGTAGAGCCT
CD23	EBVCS-5	AHS0210	TTTGATGTGGGCGGGTTGTATTACGGTTTCGAGTCT
CD73	AD2	AHS0216	AAAGTAGGGTCGATCAAGGGAGTTAACGGTAGCGCT
CD1d	CD1d42	AHS0219	GTTAGGATTATTGACGTACCGAGTTAGGAGTGATTG

**List of all 30 Human AbSeq specificities included in the BD® OMICS-One Tumor panel:**

Specificity	Clone	Oligo ID	BD® AbSeq Barcode Sequence
CD274 (PD-L1)	MIH1	AHS0004	ATCGTAAGGCTCGTGGTTCGTAAGTAAGTTCGTATC
CD279 (PD-1) †	EH12.1	AHS0014	ATGGTAGTATCACGACGTAGTAGGGTAATTGGCAGT
CD45	HI30	AHS0040	GTGCGAAATGGCGGAATGTTATCTGCGAATGTAGTC
CD324 (E-cad)	67A4	AHS0041	GATATGAATGGGTGCGGTGTAAAGTCGTAATGGTT
CD24‡	ML5	AHS0042	ACTTTGGGTGAGCGCATGATTATTCGTGACACTTT
CD90	5E10	AHS0045	GACTATATGTACGGTGTTAATTCGGGATCCTGCGCT
CD34‡	581	AHS0061	TGGGTGTATTACGGTTAGTTTATGCGCGAAGGTGTT
CD117	YB5.B8	AHS0064	GGATTAGTTGTCGTTATAGGGAGTGC GTTCTTAGCG
HLA-A,B,C	G46-2.6	AHS0066	GATATGCATGGCGAGTAGGTAGAACGAAGCTTAGGT
CD54	HA58	AHS0076	AAGAGAATATATGCGTGC GTTGTAAAGGGAATGCGT
CD29	MAR4	AHS0080	TGGTAAGGTGGTTGCGAGTAAGTAGCGGTGAGTTGT
CD47	B6H12	AHS0087	TGTTAGGTTGACGTATTATGTGTAGATCCGCAAGG
CD326 (EpCam)	EBA-1	AHS0089	TTGAGCGTAAAGTTGCGTCCGGTAATTGAGTTGCGT
CD66	B1.1/CD66	AHS0094	GTCTGCGCAAGGTAAGCTAAGTAACGAAAGGGATCT
CD133	W6B3C1	AHS0103	TTTGGTATTGGCACGGTTTGTAGCGAGTTGACGGTC
CD26	M-A261	AHS0109	TGTAGGTTGCGCGGTTATTAGGGTATTATCGATCTG
CD155	TX24	AHS0111	GCGGTGGATCGATGGGTATAGTTGGTAATTTGCGTC
CD146	P1H12	AHS0127	AGGTTATTTAGGTGACGGTTGTATTGACGAGAGAGG
C-MET	3D6	AHS0132	AGCGTGAGTTGTCGGTAGTTAATTATCGGAGAGTTT
ITGRN BTA 7	FIB504	AHS0158	TTTCAGTTTGGTCGCAGTTAAGGTATCGTATGGGTC
CD44†	L178	AHS0167	GTGATTGATTAGGACAGTTCGTTGCTTAGTAGTGGG
PECAM1 (CD31)	WM59	AHS0170	CTAAGGGACGTAATTGAGTTTCGGTGATCGCAGTTT
EphB2	2H9	AHS0176	TATTGCGGGTAGGATTTGTCTCGAAGCGTAGGTAGC
Vista	MIH65.RMAB	AHS0187	ATCAGGGAATCTCGGTAAGTTAAACGTGTATAGTGC
PDPLN	LPMAB-17	AHS0192	TTTATGAGTATTACGTCTGTTGCGATTGTTGGCGGT
NOTCH1	MHN1-519	AHS0214	CGTAGTAGGAGCGTGTTCATCGGCATTATCGTTTG
CD325 (n-Cad)	8C11	AHS0223	TAGGATGAGTTTCGTAAGTAAGGTAGTCGTATGGCT
CD58	1C3	AHS0237	TTGGTGAGTATTGGTGCGTAGTATGCGGGATGTTTG
EGFR	EGFR.1	AHS0241	ATATGATTGATGCGGGTTAGCCTACAGATTCGAGTT
CD227 (MUC1)	HMFG2	AHS0247	AGTGCATGGTTAGTAGGTGTGAGTCGTTAGATATTC

\* T-Cell and B-Cell Protein Panels contain the same CD95 antibody.

† T-Cell and Tumor Protein Panels contain the same CD279 (PD-1) and CD44 antibody.

‡ B-Cell and Tumor Protein Panels contain the same CD24 and CD34 antibody.

## Suggested Companion Products

Catalog Number	Description	Size	Clone
554656	BD Pharmingen™ Stain Buffer (FBS)	500 mL	(none)
564220	BD Pharmingen™ Human BD Fc Block	0.25 mg	Fc1
633801	BD Rhapsody™ Whole Transcriptome Analysis (WTA) Amplification Kit	1 each	(none)
633774	BD Rhapsody™ Targeted mRNA and AbSeq Amplification Kit	1 each	(none)
667058	BD Rhapsody™ TCR/BCR Next Amplification Kit	1 each	(none)
633773	BD Rhapsody™ cDNA Kit	1 each	(none)
666262	BD Rhapsody™ 8-lane cartridge	1 each	(none)
667052	BD Rhapsody™ Enhanced Cartridge Reagent V3	1 each	(none)
633781	BD® Human Single-Cell Multiplexing Kit	1 each	(none)
633849	BD® Flex Single-Cell Multiplexing Kit A, Flex Sample Tag 1–6	1 each	(none)
633850	BD® Flex Single-Cell Multiplexing Kit A, Flex Sample Tag 7–12	1 each	(none)
633851	BD® Flex Single-Cell Multiplexing Kit A, Flex Sample Tag 13–18	1 each	(none)
633852	BD® Flex Single-Cell Multiplexing Kit A, Flex Sample Tag 19–24	1 each	(none)
666625	BD Rhapsody™ HT Xpress Package	NA	(none)
633701	BD Rhapsody™ Scanner	NA	(none)
570742	BD Rhapsody™ Intracellular AbSeq Buffer Kit	1 each	(none)
570911	BD® Omics-Guard Sample Preservation Buffer	1 each	(none)
570750	BD® AbSeq Enhancer	1 each	(none)
570751	BD® RNase Inhibitor	1 each	(none)

## Product Notices

1. This reagent is provided lyophilized in a pre-titrated format.
2. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
3. Go to <https://www.bdbiosciences.com/en-us/resources/protocols/single-cell-multiomics> for additional BD Rhapsody™ protocols.
4. Go to <https://abseq-ref-gen.genomics.bd.com/> to access AbSeq reference files in FASTA format for bioinformatics analyses.
5. **Caution:** Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing. Follow state and local guidelines when disposing of hazardous waste.
6. Source of all serum proteins is from USDA inspected abattoirs located in the United States.
7. For U.S. patents that may apply, go to [bd.com/patents](http://bd.com/patents).
8. Read and understand the safety data sheets (SDSs) before handling chemicals. To obtain SDSs, go to [regdocs.bd.com](http://regdocs.bd.com) or contact BD Biosciences technical support at [researchapplications@bd.com](mailto:researchapplications@bd.com).